Indian neurotechnology startups are moving brain science beyond laboratories and hospitals, developing products that include wearables, artificial-intelligence-based diagnostics, neuromodulation systems and neurorehabilitation platforms. The shift comes as neurological disorders affect a large and diverse population in the country, creating demand for tools that can help clinicians assess, monitor and manage brain-related conditions.
For several decades, neuroscience in India was concentrated largely in universities, hospitals and research centres. The brain presents a particularly difficult medical challenge: its activity is complex, many disorders require prolonged observation, and treatment decisions often depend on information gathered over time rather than a single test. Neurotechnology companies are now attempting to make that information more measurable and usable in clinical settings.
A widening neurological-health challenge
The need for such innovation is linked to the scale of neurological illness. The Global Burden of Disease study has identified migraine as the second-leading overall cause of disability globally. The condition affects more than 1.1 billion people worldwide, including over 213 million people in India each year, according to the figures cited in the report. These numbers place migraine among the most common neurological disorders recorded and underline the potential value of better monitoring and treatment support.
Stroke is another condition whose public-health profile is changing. Once widely associated with older age, it is now being observed by doctors among people in their 30s and 40s, with unhealthy lifestyles identified as one factor in the reported trend. Alongside stroke and migraine, the wider neurological burden includes epilepsy, Parkinson’s disease, dementia, multiple sclerosis and other disorders affecting the brain and nervous system.
- Conditions mentioned: migraine, stroke, epilepsy, Parkinson’s disease, dementia and multiple sclerosis.
- Technology areas: wearables, AI-supported diagnosis, neuromodulation and neurorehabilitation.
- Clinical objective: more measurable, monitored and data-informed brain healthcare.
From research equipment to clinical workflow
One example is Marbles Health, a Delhi-based startup that has developed a portable system combining neuromodulation with electroencephalography, or EEG. EEG records electrical activity in the brain, while neuromodulation refers to approaches intended to influence nervous-system activity. Bringing the two functions into a portable ecosystem is aimed at giving specialists a way to combine intervention with monitoring.
| Product detail | Information reported |
|---|---|
| Company | Marbles Health |
| Location | Delhi |
| System | Portable neuromodulation and EEG ecosystem |
| Reported price | ₹5 lakh per unit |
| Intended users | Psychiatrists, neurologists and rehabilitation specialists |
The system is designed to support psychiatrists, neurologists and rehabilitation specialists in delivering care that is more closely measured and monitored. The report says it is intended to support work across a broader group of conditions, including addiction and eating disorders, in addition to neurological and rehabilitation applications. Its proposed role is not simply to add another device to a clinic, but to help practitioners use recorded data while planning and tracking brain-health interventions.
Promise must be matched by evidence
The emergence of these products marks an important change in how brain science may reach patients, but the presence of a device in the market does not by itself establish its effectiveness for every condition. Neurotechnology has to be assessed against the intended clinical use, the quality of its measurements and the results seen in patients. Those questions are especially important when a single platform is presented as relevant to conditions that differ substantially in their causes and treatment needs.
For India, the opportunity lies in developing technologies that are practical in real healthcare environments while responding to a large disease burden. Portable systems could be particularly relevant where access to specialised brain-care facilities is limited, although their usefulness will depend on clinical validation, trained users and sustained monitoring. The current startup activity therefore represents an early bridge between neuroscience research and healthcare delivery, rather than a final solution to the country’s neurological-health crisis.
